INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) has been a Christmas tree of joy and pain over the past 4 months, running up from $0.25/share to nearly $0.75/share, and then right back down again. The story has been an interesting one though, and that’s for sure. Traders remain compelled by IMLFF at this point, and for good reason, with the company continuing to emphasize the science out in front.
The most recent catalyst is the IMLFF’s announcement of the publication of company-sponsored research in the European Journal of Pain. The article, titled “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation”, presents results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship program. The study was conducted by Dr. Hayes Wong and Prof. Brian Cairns at the University of British Columbia and was co-authored by Dr. Sazzad Hossain, Chief Scientific Officer of InMed.
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) casts itself as a biopharmaceutical company specializing in developing cannabis-based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
IMLFF is utilizing its proprietary Intelligent Cannabinoid Drug Design Platform to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific diseases.
The big picture is that this is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools. Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.
According to company materials, “InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.”
Find out when $IMLFF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, IMLFF has been on a crazy roller-coaster ride over the past 6 months. But recently, we’ve seen a return to the company’s scientific roots, with the publication of a key research piece.
According to the release, the study results suggest that peripheral application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) may provide a valuable approach in treating severe pain. The model utilized in this study mimics muscle pain reported by sufferers of temporomandibular disorders (TMD) that affect the jaw muscles and joint. TMD is a chronic pain condition that is difficult to treat with current pain-relieving medications and more commonly affects women than men.
“Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the ‘holy grails’ in the field of analgesia”, said Dr. Sazzad Hossain, CSO of InMed. “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
We’ve witnessed above -20% stripped out of share values over the trailing month, but this action is running counter to the larger trend in the name. Market participants may want to pay attention to this stock. IMLFF has a track record that includes a number of dramatic bounces. What’s more, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed 44% over the long run average.
At this time, carrying a capital value in the market of $11.32M, IMLFF has a significant war chest ($2.7M) of cash on the books, which stands against virtually no total current liabilities. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. For continuing coverage on shares of $IMLFF stock, as well as our other breakout picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $IMLFF, either long or short, and we have not been compensated for this article.